Meeting
2020 ASCO Virtual Scientific Program
Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
Authors
Weimin Li
Astrazeneca, Gaithersburg, MD
Weimin Li , Athena Matakidou , Zara Ghazoui , Han Si , Sophie Wildsmith , Nassim Morsli , Helen Mann , Magdalena Wrona , Melissa de Los Reyes , Rajiv Raja , Craig Barker , Jessica Whiteley , Qu Zhang , Jerome Fayette , Dan Paul Zandberg , Ricard Mesia Sr., Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT002207530, NCT02319044
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6548)
DOI
10.1200/JCO.2020.38.15_suppl.6548
Abstract #
6548
Poster Bd #
209
Abstract Disclosures
Similar Posters
First Author: Michelle Wedemeyer
Poster
2021 ASCO Annual Meeting
Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.
First Author: Hsiang-fong Kao
Poster
2020 ASCO Virtual Scientific Program
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.
First Author: Sarah Verhoeff
Poster
2019 ASCO Annual Meeting
Correlation of angiogenic and immunomodulatory proteins with clinical outcomes of durvalumab (anti-PDL1) in recurrent/metastatic head and neck squamous cell carcinoma.
First Author: Xiang Guo